Growth hormone response to GRF 1-44 in children following cranial irradiation for central nervous system tumors Journal Article


Authors: Oberfield, S. E.; Kirkland, J. L.; Frantz, A.; Allen, J. C.; Levine, L. S.
Article Title: Growth hormone response to GRF 1-44 in children following cranial irradiation for central nervous system tumors
Abstract: The growth hormone (GH) responses to (A) GRF 1-44, 1 μg/kg i.v., (B) L-dopa and either arginine, insulin, or glucagon, and (C) exercise were evaluated in 10 children (3 girls, 7 boys; ages 10 years to 15 years, 8 months), 2- 10.75 years following cranial irradiation for medulloblastoma (8 patients), pineoblastoma (1 patient), and a fourth ventricular ependymoma (1 patient). Nine of the 10 children had abnormal growth rates. All children were euthyroid at the time of the study. The mean 0-60-min peak GH response to GRF (10.06 ± 2.6 ng/ml) in the patients was less than the mean peak GH response (29 ± 2.3 ng/ml) in the control children (n = 7). In 6 patients (5 with poor growth rates), a decreased GH response was noted to GRF and all other tests. Of the remaining patients, all with poor growth rates, two patients demonstrated an adequate response to GRF and pharmacologic testing; one patient had a normal GH response to GRF with a low GH response to pharmacologic testing; and one patient had a low response to GRF, despite a normal response to both exercise and pharmacologic testing. The decrease in mean peak GH response to GRF in the patient population confirms that radiation to the hypothalamic-pituitary region produces abnormalities in growth hormone release. Furthermore, in these patients, discordant GH responses to GRF and pharmacologic or physiologic tests can be observed. The abnormality in growth hormone release may result from a hypothalamic dysfunction in GRF release and/or damage to GH secretory pituicytes. © 1987 Raven Press, Ltd., New York.
Keywords: adolescent; child; clinical article; drug efficacy; combined modality therapy; brain neoplasms; growth hormone; central nervous system tumor; skull irradiation; medulloblastoma; peptide fragments; radiation injuries; insulin; ependymoma; arginine; pineal body tumor; glucagon; hypothalamo-hypophyseal system; levodopa; dwarfism; human; male; female; support, non-u.s. gov't; growth hormone releasing factor; cns lesions; growth dysfunction; somatotropin-releasing hormone
Journal Title: American Journal of Pediatric Hematology/Oncology
Volume: 9
Issue: 3
ISSN: 0192-8562
Publisher: Wolters Kluwer Health, Inc  
Date Published: 1987-01-01
Start Page: 233
End Page: 238
Language: English
PUBMED: 3118729
PROVIDER: scopus
DOI/URL:
Notes: Article -- The PDF lists the publication date as Fall -- Export Date: 5 February 2021 -- Source: Scopus; Acknowledgements: We thank Robert Sundeen for technical assistance in the performance of the growth hormone assays.
Citation Impact
MSK Authors
  1. Jeffrey Allen
    22 Allen